Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient

被引:12
作者
Gulley, JL
Dahut, WL
机构
[1] NCI, Ctr Canc Res, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA
[2] NCI, Genitourinary Clin Res Sect, Med Oncol Clin Res Unit, Bethesda, MD 20892 USA
[3] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
D O I
10.1016/j.urology.2003.08.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
For >50 years, the standard treatment for advanced prostate cancer has been hormonal therapy. However, all such treated patients eventually develop disease refractory to androgen suppression as manifested by increasing prostate-specific antigen (PSA) levels, progressive disease on radiographic imaging, and ultimately, symptomatic deterioration. Historical perceptions that treatment of hormone-refractory prostate cancer was a largely futile venture have faded over the past decade with the advances in new therapeutic strategies. With the use of PSA values to follow the progress of patients after definitive therapy, physicians are seeing more patients who have failed hormonal therapy yet have no symptoms from their disease. There are standard therapies available for patients who require palliation for symptoms, but there is no consensus on treatment for asymptomatic patients. To date, there has been no definitive increase in survival with any therapy in this group of patients. In addition, several novel drugs have advanced through preclinical testing into early clinical trials. It is these drugs-alone or in combination-that are designed to target strategic tumor pathways in these patients. This article will review a selection of agents that may be potentially useful in this population. (C) 2003 Elsevier Inc.
引用
收藏
页码:147 / 154
页数:8
相关论文
共 79 条
  • [1] Adib RS, 1997, BRIT J UROL, V79, P235
  • [2] ESTRACYT IN ADVANCED-CARCINOMA OF THE BREAST - PHASE-II STUDY
    ALEXANDER, NC
    HANCOCK, AK
    MASOOD, MB
    PEET, BG
    PRICE, JJ
    TURNER, RL
    STONE, J
    WARD, AJ
    [J]. CLINICAL RADIOLOGY, 1979, 30 (02) : 139 - 147
  • [3] [Anonymous], P AM SOC CLIN ONCOL
  • [4] ARLEN P, 2003, P AN M AM SOC CLIN, V22, pA1701
  • [5] Arlen PM, 2003, J UROLOGY, V169, P243
  • [6] Banerjee D, 1999, CURR OPIN MOL THER, V1, P404
  • [7] Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
    Beer, TM
    Pierce, WC
    Lowe, BA
    Henner, WD
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (09) : 1273 - 1279
  • [8] Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: Feasibility and preliminary results
    Ben-Josef, E
    Porter, AT
    Han, S
    Mertens, W
    Chuba, P
    Fontana, J
    Hussain, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (03): : 699 - 703
  • [9] Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate
    Berry, W
    Dakhil, S
    Gregurich, MA
    Asmar, L
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (04) : 8 - 15
  • [10] Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
    Bolla, M
    Gonzalez, D
    Warde, P
    Dubois, JB
    Mirimanoff, RO
    Storme, G
    Bernier, J
    Kuten, A
    Sternberg, C
    Gil, T
    Collette, L
    Pierart, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) : 295 - 300